| Literature DB >> 35528360 |
Abstract
Objective: To explore the effect of applying Dahuang Zhechong pills (DHZCP) from Jingui Yaolue to patients with early-to-mid prostate cancer undergoing radical resection and carry out a theoretical clinical study of traditional Chinese medicine (TCM) to verify the effect of DHZCP formula under the guidance of TCM theory.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35528360 PMCID: PMC9068324 DOI: 10.1155/2022/2998825
Source DB: PubMed Journal: Comput Intell Neurosci
Between-group comparison of clinical data (n = 49).
| Item | Group A | Group B |
|
|
|---|---|---|---|---|
| Mean age (Mean ± SD, years) | 61.04 ± 3.86 | 60.57 ± 3.82 | 0.683 | 0.496 |
| Mean course of disease (Mean ± SD, months) | 27.42 ± 2.66 | 26.87 ± 2.31 | 1.093 | 0.277 |
| Gleason score (Mean ± SD, points) | 4.12 ± 0.99 | 4.22 ± 1.16 | 0.459 | 0.647 |
| KPS score (Mean ± SD, points) | 78.47 ± 4.06 | 78.31 ± 3.71 | 0.204 | 0.839 |
| Pathological type | ||||
| Cystadenocarcinoma | 43 (87.76%) | 45 (91.84%) | 0.446 | 0.505 |
| Squamous cell carcinoma | 1 (2.04%) | 2 (4.08%) | 0.344 | 0.558 |
| Neuroendocrine carcinoma | 5 (10.20%) | 2 (4.08%) | 1.385 | 0.239 |
| Tumor stage | 0.176 | 0.675 | ||
| Early | 32 (65.31%) | 30 (61.22%) | ||
| Mid-term | 17 (34.69%) | 19 (38.78%) | ||
| Educational degree | ||||
| College | 2 (4.08%) | 5 (10.20%) | 1.385 | 0.239 |
| High school | 21 (42.86%) | 22 (44.90%) | 0.041 | 0.839 |
| Primary school | 26 (53.06%) | 22 (44.90%) | 0.653 | 0.419 |
| Place of residence | 0.165 | 0.685 | ||
| Urban area | 21 (42.86%) | 23 (46.94%) | ||
| Rural area | 28 (57.14%) | 26 (53.06%) | ||
Between-group comparison of complication treatment effect within 3 months (n (%)).
| Group |
| Urinary irritation syndrome | Abnormal defecation | Anal, rectal, and perineal tenesmus, swelling, and pain | Total effective rate |
|---|---|---|---|---|---|
| A | 49 | 0 | 0 | 0 | 0 |
| B | 49 | 4 (8.16) | 2 (4.08) | 3 (6.12) | 18.37 (9/49) |
|
| 9.910 | ||||
|
| <0.05 |
Between-group comparison of complication treatment effect within 3–4 months (n (%)).
| Group |
| Urinary irritation syndrome | Abnormal defecation | Anal, rectal, and perineal tenesmus, swelling, and pain | Total effective rate |
|---|---|---|---|---|---|
| A | 49 | 3 (6.12) | 2 (4.08) | 3 (6.12) | 16.33 (8/49) |
| B | 49 | 9 (18.37) | 10 (20.41) | 8 (16.33) | 55.10 (27/49) |
|
| 16.044 | ||||
|
| <0.001 |
Between-group comparison of complication treatment effect within 4–6 months (n (%)).
| Group |
| Urinary irritation syndrome | Abnormal defecation | Anal, rectal, and perineal tenesmus, swelling, and pain | Total effective rate |
|---|---|---|---|---|---|
| A | 49 | 5 (10.20) | 4 (8.16) | 4 (8.16) | 26.53 (13/49) |
| B | 49 | 19 (38.78) | 13 (26.53) | 11 (22.45) | 87.76 (43/49) |
|
| 37.500 | ||||
|
| <0.001 |
Figure 1Between-group comparison of mental status after treatment [Mean ± SD]. Note: the horizontal axis indicated groups B and A, and the vertical axis indicated the HAMA score (points). After treatment, the mean HAMA score of groups B and A was, respectively, (15.61 ± 1.44) and (18.67 ± 1.31); indicated significant between-group difference in mean HAMA score after treatment (t = 11.003 and P < 0.001).
Between-group comparison of biological recurrence status during follow-up (n (%)).
| Item | Group A ( | Group B ( |
|
|
|---|---|---|---|---|
| Biological recurrence/months | ||||
| 0–30 | 0 | 0 | ||
| 31–48 | 1 (2.04) | 0 | ||
| 49–60 | 3 (6.12) | 1 (2.04) | ||
| Total | 4 (8.16) | 1 (2.04) | 1.897 | 0.168 |
| Clinical recurrence/months | ||||
| 0–30 | 0 | 0 | ||
| 31–48 | 0 | 0 | ||
| 49–60 | 3 (6.12) | 0 | ||
| Total | 3 (6.12) | 0 | 3.095 | 0.079 |